Neuraxpharm aims for €500 million in net sales in 2024, up 13.6% from €440 million last year, driven by its focus on CNS disorder treatments. Acquisitions,...
In 2023, Bayer hoped to have a sales volume of between €51 billion and €52 billion, which is now reduced to between €48.5 billion and €49.5 billion,...